Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) PT at $56.57

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $56.57.

A number of analysts have recently weighed in on AGIO shares. Royal Bank of Canada increased their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 price target on the stock. Scotiabank boosted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th.

Agios Pharmaceuticals Stock Down 4.8 %

Shares of Agios Pharmaceuticals stock opened at $30.76 on Friday. The firm’s 50 day moving average price is $33.29 and its 200-day moving average price is $41.11. The company has a market cap of $1.76 billion, a P/E ratio of 2.71 and a beta of 0.90. Agios Pharmaceuticals has a 52-week low of $27.14 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities research analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AGIO. State Street Corp grew its position in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $33,767,000. BNP Paribas Financial Markets raised its holdings in shares of Agios Pharmaceuticals by 15.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock valued at $531,000 after purchasing an additional 1,570 shares in the last quarter. FMR LLC lifted its position in shares of Agios Pharmaceuticals by 283.2% during the 3rd quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock worth $2,017,000 after purchasing an additional 33,546 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Agios Pharmaceuticals during the third quarter worth $892,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.